Acadia Pharmaceuticals announced that the U.S. Food and Drug Administration has approved DAYBUE for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. DAYBUE is the first and only drug approved for the treatment of Rett syndrome. The FDA approval of DAYBUE was supported by results from the pivotal Phase 3 LAVENDER study evaluating the efficacy and safety of trofinetide versus placebo in 187 female patients with Rett syndrome five to 20 years of age. DAYBUE is expected to be available in the U.S. by the end of April, 2023. With the FDA approval of DAYBUE, Acadia has received a Rare Pediatric Disease Priority Review Voucher, which can be used to obtain priority review for a subsequent application.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $24 from $20 at Canaccord
- This ETF Has 67% Upside Potential, According to Analysts
- Acadia Pharmaceuticals price target raised to $27 from $19 at RBC Capital
- Acadia Pharmaceuticals price target raised to $19 from $15 at Mizuho
- Acadia Pharmaceuticals sees FY23 revenue $520M-$550M, consensus $569.2M